dc.contributor.author | Canbaz, Hayri | |
dc.contributor.author | Idiz, Ufuk Ofuz | |
dc.contributor.author | Dal, Hayriye Cankar | |
dc.contributor.author | Kaciroglu, Fatih | |
dc.contributor.author | Tas, Seher | |
dc.contributor.author | Cubukcu, Hikmet Can | |
dc.contributor.author | Bestemir, Attila | |
dc.date.accessioned | 2024-02-04T13:29:33Z | |
dc.date.available | 2024-02-04T13:29:33Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 1300-7777 | |
dc.identifier.issn | 1308-5263 | |
dc.identifier.uri | https://doi.org/10.4274/tjh.galenos.2022.2022.0103 | |
dc.identifier.uri | https://search.trdizin.gov.tr/yayin/detay/1174275 | |
dc.identifier.uri | http://hdl.handle.net/11446/4680 | |
dc.description.abstract | Objective: Many methods are used in the treatment of coronavirus disease 2019 (COVID-19), which causes acute respiratory distress syndrome (ARDS), and there are conflicting reports in the literature regarding the results of mesenchymal stem cell (MSC) therapy, which is one of those methods. The aim of our study is to evaluate the effect of MSC treatment applied together with standard treatments on survival. Materials and Methods: This retrospective case-control study evaluates the survival effect of MSC treatment administered to patients treated in intensive care after the development of ARDS due to COVID-19 between March 2020 and March 2021. The age, gender, comorbid disease status, APACHE II score, and overall and comorbidity-based survival rates were compared between patients who received standard medical treatment (SMT) and patients who received MSC treatment together with SMT. Results: There were 62 patients in the group receiving only SMT and 81 patients in the group receiving SMT and MSC. No difference was observed between the groups in terms of age, gender, presence of comorbid diseases, or APACHE II scores. There were also no differences according to Kaplan-Maier analysis for the survival statuses of the groups. There was no serious adverse effect due to MSC treatment among these patients. Conclusion: Our study presents the largest case series in the literature, and it was observed that MSC treatment may not significantly affect overall survival or comorbid disease-based survival, in contrast to many other studies in the literature. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Galenos Publ House | en_US |
dc.relation.ispartof | Turkish Journal Of Hematology | en_US |
dc.identifier.doi | 10.4274/tjh.galenos.2022.2022.0103 | |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Mesenchymal stem cell | en_US |
dc.subject | Emergency | en_US |
dc.subject | Mortality | en_US |
dc.subject | Survival | en_US |
dc.title | Effectiveness of Mesenchymal Stem Cell Therapy for COVID-19 Patients in the Intensive Care Unit: A Case-Control Study | en_US |
dc.type | article | en_US |
dc.department | DBÜ | en_US |
dc.identifier.issue | 4 | en_US |
dc.identifier.volume | 39 | en_US |
dc.identifier.startpage | 222 | en_US |
dc.identifier.endpage | 229 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.department-temp | [Canbaz, Hayri] Yildirim Beyazit Univ, Yenimahalle Training & Res Hosp, Emergency Serv, Ankara, Turkey; [Idiz, Ufuk Ofuz] Univ Hlth Sci Turkey, Istanbul Training & Res Hosp, Clin Gen Surg, Istanbul, Turkey; [Dal, Hayriye Cankar] Univ Hlth Sci Turkey, Ankara City Hosp, Clin Intens Care Unit, Ankara, Turkey; [Kaciroglu, Fatih] Gen Directorate Hlth Serv, Tissue Organ Transplantat & Dialysis Serv Dept, Ankara, Turkey; [Tas, Seher] Gen Directorate Hlth Serv, Dept Tissue Organ Transplantat & Dialysis Serv, Organ Transplantat Unit, Ankara, Turkey; [Cubukcu, Hikmet Can] Ankara Univ, Stem Cell Inst, Interdisciplinary Stem Cells & Regenerat Med, Ankara, Turkey; [Bestemir, Attila] Istanbul Bakirkoy Dr Sadi Konuk Training & Res Ho, Emergency Serv, Istanbul, Turkey; [Gulsen, Murat] Ankara Diskapi Yildirim Beyazit Training & Res Ho, Clin Pediat, Ankara, Turkey; [Polat, Istemi Taha] Horasan State Hosp, Clin Anesthesiol & Reanimat, Agri, Turkey; [Laloglu, Abubekir] Ataturk Univ, Fac Dent, Dept Oral Dent & Maxillofacial Radiol, Erzurum, Turkey; [Tor, Ibrahim Hakki] Erzurum City Hosp, Clin Anesthesiol & Reanimat, Erzurum, Turkey; [Akkurt, Halik Ekrem] Konya Numune Hosp, Clin Phys Med & Rehabil, Konya, Turkey; [Ates, Utku] Istanbul Bilim Univ, Fac Med, Dept Histol & Embryol, Istanbul, Turkey; [Reisli, Ismail] Necmettin Erbakan Univ, Meram Med Fac | en_US |
dc.authorid | Gülşen, Murat/0000-0003-4494-9536 | |
dc.authorid | Çubukçu, Hikmet Can/0000-0001-5321-9354 | |
dc.authorid | cankar dal, hayriye/0000-0003-4744-9959 | |
dc.authorid | Gülşen, Murat/0000-0003-4494-9536 | |
dc.authorid | Idiz, Ufuk Oguz/0000-0002-8462-7809 | |
dc.identifier.pmid | 36250478 | en_US |
dc.identifier.scopus | 2-s2.0-85143088554 | en_US |
dc.identifier.wos | WOS:000968447700001 | en_US |
dc.authorwosid | Gülşen, Murat/AAX-9638-2021 | |
dc.authorwosid | Çubukçu, Hikmet Can/Y-9179-2018 | |
dc.authorwosid | Gülşen, Murat/JAC-4383-2023 | |
dc.authorwosid | cankar dal, hayriye/ABP-0759-2022 | |
dc.authorwosid | Idiz, Ufuk Oguz/N-1794-2019 | |
dc.identifier.trdizinid | 1174275 | en_US |